If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  Ranibizumab Decreases Macular Oedema and Increases Visual Acuity in Patients With Central Retinal Vein Occlusion: Presented at ARVO By Micheal Casasnovas FORT LAUDERDALE, Fla -- May 5, 2008 -- Treatment with the vascular endothelial growth factor inhibitor ranibizumab decreases macular oedema while improving best-corrected visual acuity, according to research presented here at the Association for Research on Vision and Ophthalmology (ARVO) 2008 Annual Meeting. "The interim analysis reveals that among the patients who have completed the study so far, ranibizumab tends to decrease macular oedema with a corresponding increase in best-corrected visual acuity," said Bettina Kinge, MD, Head, Retinaklinikken Aleris, Oslo, Norway, in her poster presentation on April 29. Dr. Kinge and colleagues enrolled 17 men and 15 women in a 6-month follow-up multicentre study. The patients received 3 monthly intravitreal injections of ranibizumab 0.5 mg or placebo. Patients received retreatment at the physician's discretion through the duration of the study. Patients had a mean age of 72 years (range, 52-88 years). Mean best-corrected visual acuity at baseline was 41 letters, with a corresponding mean macular thickness of 622 mcm. Among the 6 patients in the treatment group who received at least 3 injections, best-corrected visual acuity changed from 30 letters at baseline to 47 letters after treatment. In comparison, the best-corrected visual acuity among the 9 patients who received placebo injections changed from 44 letters at baseline to 42 letters after treatment. During the same period of the study, mean macular thickness changed from 622 to 191 mcm among treated patients compared with a change from 572 to 431 mcm in the placebo group. The study excluded 1 patient in the treatment group because of a retinal arterial occlusion after the first injection. Two patients in the treatment group required an additional injection and 2 patients needed 2 injections. Some patients experienced a decrease in their best-corrected visual acuity and a rapid increase in macular oedema when they did not receive the injection every month. Funding for this study was provided by Novartis.
[Presentation title: The ROCC-study: A Randomized Study Comparing the Safety and Efficacy of Ranibizumab (Lucentis(R)) to Sham in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO). Poster A482]
|
